Your search for tysabri returned 17 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

Your search for tysabri returned 17 results

Sort Results:

Relevant Recent

Tysabri gains Crohn’s disease indication

The FDA has approved the use of Tysabri (natalizumab, from Biogen Idec) for the treatment of moderate-to-severe Crohn's disease in patients with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional Crohn's disease therapies.

FDA issues Tysabri warning

The FDA is warning healthcare providers of reported hepatic injury associated with Tysabri (natalizumab, from Biogen Idec).
Drug Monograph Updates

October 2019 Recap of Drug Updates

The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of October. The chart below provides highlights of key monograph updates made this month (not an inclusive list). Click on the name of the drugs to view the full monographs on Key: D=Dosing,…